#RemeOs™ #Bioretec #Finland #Tampere #Activa

Bioretec's Ambitious Strategy for the Future

Bioretec Ltd, a Finnish medical device company, has announced a comprehensive update to its strategy for the upcoming period of 2026-2028. The updated strategy focuses heavily on commercial performance and aims to bolster sales both within the United States and in international markets. The company's recent communications highlight a commitment to advancing innovative, biodegradable implant technologies, fundamentally transforming the orthopedic care landscape.

Key Strategic Pillars

The updated strategy is built on three primary pillars:

1. Industry Leading Innovation: Bioretec is focused on pioneering state-of-the-art materials science that can improve patient outcomes. The emphasis is on demonstrating healing through the absorption of their innovative materials.

2. Robust Clinical and Economic Evidence Generation: The company aims to expand its patent portfolio while generating strong clinical data, which is crucial for affirming its competitive advantage in the market.

3. Global Commercial Excellence: Bioretec plans to enhance its commercial performance by developing high-value repeatable business strategies and collaborating with top-tier partners worldwide.

Strategic Priorities

To achieve its goals by 2028, Bioretec has outlined several strategic priorities:

• - Innovate consistently by introducing at least one new product or indication every 12 to 18 months, thereby ensuring ongoing R&D investments.
• - Establish a strong market presence in the U.S. through effective distribution and targeted engagement strategies with key opinion leaders.
• - Revamp the commercial strategy for international markets with clear partner selection and ambitious commercialization targets, specifically targeting the launch of its RemeOs™ product line in high-value regions.

Financial Targets

Reflecting its strategic objectives, Bioretec has set ambitious financial targets:

• - Achieve net sales exceeding €10 million by 2028.
• - Maintain a sales margin above 70% throughout the strategic period.

Given the nature of strategic investments planned for R&D and commercialization, Bioretec does not anticipate reaching cash flow positivity during this period, indicating a strong reinvestment philosophy.

Product Pipeline Expansion

Bioretec's current product offerings include the Activa and RemeOs™ families. The company is particularly focused on the RemeOs™ line, which features innovative absorbable metal alloy technology designed for larger bone fractures, capable of bearing significant loads.

Bioretec has further segmented its product pipeline into three developmental timelines:
1. Short Term (<18 months): Introduces new trauma screws, drill pins, and headless cannulated screws tailored to specific orthopedic needs.
2. Medium Term (18-36 months): Launch of differentiated absorbable trauma products to cater to a wider range of orthopedic injuries.
3. Long Term (36+ months): Plans to expand into spinal portfolios and other essential orthopedic hardware solutions.

About Bioretec

Founded in Finland, Bioretec has a profound commitment to revolutionizing orthopedic treatments through its expertise in biodegradable implant technologies. The introduction of its RemeOs™ product line, based on high-performance materials, aims to enhance surgical outcomes while alleviating the need for removal surgeries, offering a dual benefit of efficacy and patient satisfaction.

With a vision to become a recognized leader in the global orthopedic market, Bioretec is well-positioned for growth, aiming to leverage the strategic review to maximize shareholder value and ensure patient needs are at the forefront of innovation. The journey through 2026-2028 promises exciting developments in orthopedic care, with Bioretec leading the charge to make surgery simpler and more effective for patients worldwide.